



## PHARMACEUTICAL 2020









## PHARMACEUTICAL 2020



## Xencor Inc Rank 20 of 362



The relative strengths and weaknesses of Xencor Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xencor Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 247% points. The greatest weakness of Xencor Inc is the variable Intangible Assets, reducing the Economic Capital Ratio by 0.55% points.

The company's Economic Capital Ratio, given in the ranking table, is 205%, being 508% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	558,405
Cost of Goods Sold	0
Intangible Assets	14,421
Liabilities, Current	66,558
Liabilities, Non-Current	10,491
Other Assets	81,619
Other Compr. Net Income	2,132
Other Expenses	312
Other Liabilities	0
Other Net Income	13,363
Property and Equipment	15,805
Research and Development	118,590
Revenues	156,700
Selling, General and Administrative Expense	24,286

Output Variable	Value in 1000 USD
Assets	670,250
Liabilities	77,049
Expenses	143,188
Stockholders Equity	593,201
Net Income	26,875
Comprehensive Net Income	27,941
Economic Capital Ratio	205%